The Food and Drug Administration has announced that it will fast-track the approval of a drug called selinexor sold under the brand name Xpovio for the treatment of a type of blood cancer called relapsed refractory multiple myeloma (RRMM). The approval will only be granted for certain adult patients who haven’t responded well to other treatment options. RRMM is blood …